Developing a Novel Image Marker to Predict the Responses of Neoadjuvant Chemotherapy (NACT) for Ovarian Cancer Patients
OBJECTIVE: Neoadjuvant chemotherapy (NACT) is one kind of treatment for advanced stage ovarian cancer patients. However, due to the nature of tumor heterogeneity, the patients' responses to NACT varies significantly among different subgroups. To address this clinical challenge, the purpose of this study is to develop a novel image marker to achieve high accuracy response prediction of the NACT at an early stage.
METHODS: For this purpose, we first computed a total of 1373 radiomics features to quantify the tumor characteristics, which can be grouped into three categories: geometric, intensity, and texture features. Second, all these features were optimized by principal component analysis algorithm to generate a compact and informative feature cluster. Using this cluster as the input, an SVM based classifier was developed and optimized to create a final marker, indicating the likelihood of the patient being responsive to the NACT treatment. To validate this scheme, a total of 42 ovarian cancer patients were retrospectively collected. A nested leave-one-out cross-validation was adopted for model performance assessment.
RESULTS: The results demonstrate that the new method yielded an AUC (area under the ROC [receiver characteristic operation] curve) of 0.745. Meanwhile, the model achieved overall accuracy of 76.2%, positive predictive value of 70%, and negative predictive value of 78.1%.
CONCLUSION: This study provides meaningful information for the development of radiomics based image markers in NACT response prediction.
| Errataetall: |
UpdateIn: Comput Biol Med. 2024 Feb 27;172:108240. - PMID 38460312 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
ArXiv - (2023) vom: 13. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Ke [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 24.03.2024 published: Electronic UpdateIn: Comput Biol Med. 2024 Feb 27;172:108240. - PMID 38460312 Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM362409277 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362409277 | ||
| 003 | DE-627 | ||
| 005 | 20240325234308.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1346.xml |
| 035 | |a (DE-627)NLM362409277 | ||
| 035 | |a (NLM)37744460 | ||
| 035 | |a (PII)arXiv:2309.07087v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Ke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Developing a Novel Image Marker to Predict the Responses of Neoadjuvant Chemotherapy (NACT) for Ovarian Cancer Patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Comput Biol Med. 2024 Feb 27;172:108240. - PMID 38460312 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a OBJECTIVE: Neoadjuvant chemotherapy (NACT) is one kind of treatment for advanced stage ovarian cancer patients. However, due to the nature of tumor heterogeneity, the patients' responses to NACT varies significantly among different subgroups. To address this clinical challenge, the purpose of this study is to develop a novel image marker to achieve high accuracy response prediction of the NACT at an early stage | ||
| 520 | |a METHODS: For this purpose, we first computed a total of 1373 radiomics features to quantify the tumor characteristics, which can be grouped into three categories: geometric, intensity, and texture features. Second, all these features were optimized by principal component analysis algorithm to generate a compact and informative feature cluster. Using this cluster as the input, an SVM based classifier was developed and optimized to create a final marker, indicating the likelihood of the patient being responsive to the NACT treatment. To validate this scheme, a total of 42 ovarian cancer patients were retrospectively collected. A nested leave-one-out cross-validation was adopted for model performance assessment | ||
| 520 | |a RESULTS: The results demonstrate that the new method yielded an AUC (area under the ROC [receiver characteristic operation] curve) of 0.745. Meanwhile, the model achieved overall accuracy of 76.2%, positive predictive value of 70%, and negative predictive value of 78.1% | ||
| 520 | |a CONCLUSION: This study provides meaningful information for the development of radiomics based image markers in NACT response prediction | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Abdoli, Neman |e verfasserin |4 aut | |
| 700 | 1 | |a Gilley, Patrik |e verfasserin |4 aut | |
| 700 | 1 | |a Sadri, Youkabed |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xuxin |e verfasserin |4 aut | |
| 700 | 1 | |a Thai, Theresa C |e verfasserin |4 aut | |
| 700 | 1 | |a Dockery, Lauren |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Kathleen |e verfasserin |4 aut | |
| 700 | 1 | |a Mannel, Robert S |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Yuchen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ArXiv |d 2020 |g (2023) vom: 13. Sept. |w (DE-627)NLM310900107 |x 2331-8422 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:13 |g month:09 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 13 |c 09 | ||